Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Nipro Aims at 100 Billion Yen Sales for Pharma Biz by FY2020, Seeking No. 1 Spot among Research-Oriented Makers in Generic Field
October 5, 2017
- Humira Designated as Orphan Drug for Hidradenitis Suppurativa: AbbVie
October 5, 2017
- Sato, Eisai to Copromote Oral Onychomycosis Drug
October 4, 2017
- Takeda’s Oral Relugolix Scores Non-Inferiority vs Leuprorelin in Uterine Fibroids: Japan PIII
October 4, 2017
- Takeda-Backed Chromatography Startup Launched at Shonan Research Center
October 4, 2017
- Trazenta-Jardiance Combo Filed in Japan: Lilly/Boehringer
October 4, 2017
- EA Pharma, Mochida in Tie-Up Deal for 2nd Constipation Med
October 4, 2017
- Torii Named CEO of Fujifilm-Kyowa Kirin JV after Humira Biosimilar Filing
October 4, 2017
- JT and Bayer Begin Japan PIII for HIF-PH Inhibitors, Follow Astellas and GSK
October 4, 2017
- Celgene Looks to Expand Footprint in Japan Unmet Need Arena
October 4, 2017
- Japan Debut of MSD’s Zetia/Lipitor Combo Delayed as Cyberattack Woes Continue
October 4, 2017
- Shoichiro Ogawa Tapped as Alcon Pharma Japan Chief
October 3, 2017
- Olaparib Gets Orphan Status for BRCA-Mutated Breast Cancer
October 3, 2017
- Astellas to Launch 3-Way Copromotion Scheme for Kiklin
October 3, 2017
- Yoshindo Licenses Nesp Biosimilar from South Korea’s CJ Healthcare
October 3, 2017
- AZ Contesting Employee Lawsuits; First Oral Arguments Held at Tokyo District Court
October 3, 2017
- JCR Files Fabrazyme Biosimilar for Japan Approval
October 3, 2017
- SI-613 Enters PIIb Study for Enthesopathy: Ono, Seikagaku
October 3, 2017
- Takeda Links with Swedish, Canadian Organizations on IBD Research
October 2, 2017
- Opdivo-Yervoy Combo Filed in Japan for Melanoma
October 2, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…